معرفی
Andrew E. Aplin serves as Kalbach-Newton Professor in Cancer Research within the Department of Pharmacology, Physiology, & Cancer Biology at Thomas Jefferson University's College of Life Sciences. His laboratory investigates melanoma pathogenesis with emphasis on mutant B-RAF signaling pathways driving tumor progression and therapeutic resistance.
Research centers on molecular mechanisms of melanocyte transformation, including Bcl-2 family proteins in cell survival, integrin-mediated adhesion dynamics, Rnd3 GTPase functions in 3D invasion, and FOXD3 stemness factor upregulation following RAF inhibition. Current work focuses on elucidating resistance mechanisms to kinase inhibitors through combinatorial approaches targeting FAK and RAF-MEK pathways.
Publication analysis reveals concentrated efforts on overcoming resistance in BRAF V600E melanoma and uveal melanoma subtypes, with recent work exploring metabolic inhibition-induced pyroptosis and RAF-MEK clamp strategies. Dr. Aplin actively contributes to global melanoma research initiatives including the 2023 CURE OM Global Science Meeting.
His laboratory employs molecular inhibitor approaches, clinical-grade therapeutic testing, 3D skin mimetic in vitro systems, and intradermal in vivo imaging models to characterize melanoma progression across disease stages.
